Novanta Inc. experienced a marked 35.5% revenue growth in fiscal 2025, signaling a strong demand rebound primarily in its advanced industrial markets. Despite top-line momentum, operating income declined by 15%, net income fell 16%, and operating cash flow plunged nearly 60%, revealing margin and working capital challenges. The company's heavy reliance on a handful of OEM customers accounting for over 40% of sales injects volatility into its operating profile amid cyclical microelectronics demand. Regulatory burdens—especially in medical device approvals—heighten compliance costs and add uncertainty. Capital allocation reflects aggressive stock buybacks funded amid weakening cash flow, driving an equity base expansion but resulting in modest returns on equity near 4%. Upcoming earnings releases and order trends will be critical to gauge sustainability amid geopolitical and currency considerations.